Search Results - "A.F. Shields"

Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status by E.B. Faber, Y. Baca, J. Xiu, P. Walker, G. Manji, S. Gholami, A. Saeed, A. Prakash, G.P. Botta, D. Sohal, H.J. Lenz, A.F. Shields, C. Nabhan, W. El-Deiry, A. Seeber, V. Chiu, J. Hwang, E. Lou

“…Background: The majority of pancreatic ductal adenocarcinomas (PDACs) are driven by mutant (mt) KRAS. How mt KRAS and co-driver mutations affect the immune…”
Get full text

Phase II Study of Gemcitabine, Cisplatin, and Infusional Fluorouracil in Advanced Pancreatic Cancer by EL-RAYES, B. F, ZALUPSKI, M. M, SHIELDS, A. F, VAISHAMPAYAN, U, HEILBRUN, L. K, JAIN, V, ADSAY, V, DAY, J, PHILIP, P. A

“…This phase II study was undertaken to determine the efficacy of adding infusional fluorouracil (FU) to the chemotherapy doublet of gemcitabine and cisplatin in…”
Get full text

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer by Grothey, Axel, Sobrero, Alberto F, Shields, Anthony F, Yoshino, Takayuki, Paul, James, Taieb, Julien, Souglakos, John, Shi, Qian, Kerr, Rachel, Labianca, Roberto, Meyerhardt, Jeffrey A, Vernerey, Dewi, Yamanaka, Takeharu, Boukovinas, Ioannis, Meyers, Jeffrey P, Renfro, Lindsay A, Niedzwiecki, Donna, Watanabe, Toshiaki, Torri, Valter, Saunders, Mark, Sargent, Daniel J, Andre, Thierry, Iveson, Timothy

“…This analysis involving patients with stage III colon cancer pooled the findings of six clinical trials regarding the effect of adjuvant-therapy duration on…”
Get full text

Experience with 177Lu-Dotatate in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors at a Single Urban Cancer Center by Kieft, A.L., Ibrahim, Y., Dyson, G., Baran, G., Azmi, A., Hallak, M.N. Al, Shields, A.F., Vaishampayan, N.G., Philip, P.

“…177Lu-Dotatate is an FDA approved peptide receptor radiotherapeutic (PRRT) agent for metastatic well differentiated midgut neuroendocrine tumors (NETs)…”
Get full text

1242 Cediranib in combination with mFOLFOX6: results from the cohort expansion phase of a two-part Phase I study by LoRusso, P, Zalupski, M, Desai, S, Burris, H.A, Stella, P.J, Xu, J, Liu, Q, Mookerjee, B, Shields, A.F

Get full text

468 POSTER The role of thymidine kinase and thymidylate synthase in the response of tumor cells to the suicide prodrug 2′-F-ara-deoxyuridine by Phatak, P, Daniels, C.M, Shields, A.F, Collins, J.M, LoRusso, P.M, Burger, A.M

Get full text

537P A phase I/II study of oral chk1 inhibitor LY2880070 in combination with low-dose gemcitabine in patients with advanced or metastatic ovarian cancer by Miller, W.H., Shields, A.F., Provencher, D., Gilbert, L., Shapiro, G., Oza, A.M., Spratlin, J., Lheureux, S., Bhat, G., Salvador, S., Nunes, P., Lau, S., Weiner, I., Keene, J., Zaknoen, S., Smith, P., Stille, J., Vincett, D., Chu, Q.S-C.

Get full text

1004P Initial results from a phase I study of Nous-209, an off-the-shelf viral vectored immunotherapy encoding 209 shared frame shift peptide neoantigens, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability by Overman, M.J., Leoni, G., D'Alise, A.M., Cotugno, G., Langone, F., Capone, S., Del Sorbo, M., Fakih, M., Le, D.T., Shields, A.F., Pedersen, K.S., Shah, M.A., Mukherjee, S., Delaite, P., Faivre, T., Scarselli, E.

Get full text

454P CCR5/CCL5 gene expression in colorectal cancer (CRC): Comprehensive profiling and clinical value by Battaglin, F., Baca, J., Xiu, J., Shields, A.F., Goldberg, R.M., Arai, H., Wang, J., Jayachandran, P., Kawanishi, N., Lenz, A., Soni, S., Seeber, A., Abraham, J., Lou, E., Philip, P.A., Weinberg, B.A., Zhang, W., Marshall, J.L., Korn, W.M., Lenz, H-J.

Get full text

317MO Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: An ACCENT/IDEA pooled analysis of 12 trials by Gallois, C., Shi, Q., Meyers, J., André, T., Iveson, T.J., Sobrero, A.F., Alberts, S., de Gramont, A., Meyerhardt, J., Shields, A.F., Georges, T., Schmoll, H.J.E-V., Souglakos, I., Kerr, R., Lonardi, S., Yothers, G., Yoshino, T., Goldberg, R., Taieb, J., Papamichael, D.

Get full text

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? by Sobrero, A., Grothey, A., Iveson, T., Labianca, R., Yoshino, T., Taieb, J., Maughan, T., Buyse, M., André, T., Meyerhardt, J., Shields, A.F., Souglakos, I., Douillard, J.-Y., Cervantes, A.

“…Six months of adjuvant oxaliplatin-based chemotherapy is standard for patients with stage III colon cancer following surgery. However, oxaliplatin is…”
Get full text

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS–MAPK pathway and TP53 as potential predictors of immunotherapy efficacy by Wang, J.Y., Xiu, J., Baca, Y., Arai, H., Battaglin, F., Kawanishi, N., Soni, S., Zhang, W., Millstein, J., Shields, A.F., Grothey, A., Weinberg, B.A., Marshall, J.L., Lou, E., Khushman, M., Sohal, D.P.S., Hall, M.J., Oberley, M., Spetzler, D., Shen, L., Korn, W.M., Lenz, H.J.

“…The impact of molecular alterations on programmed death-ligand 1 (PD-L1) combined positive score (CPS) is not well studied in gastroesophageal adenocarcinomas…”
Get full text

1952P Comprehensive profiling of MDM2 amplified gastrointestinal (GI) cancers by Battaglin, F., Xiu, J., Baca, Y., Shields, A.F., Goldberg, R.M., Puccini, A., Tokunaga, R., Arai, H., Wang, J., Kawanishi, N., Seeber, A., Astaturov, I., Lockhart, A.C., Zhang, W., Marshall, J.L., Korn, W.M., Lenz, H.J.

Get full text

1882PD - Comprehensive molecular characterization of brain metastases (BM) from colorectal cancer (CRC) by Battaglin, F., Xiu, J., Baca, Y., Goldberg, R.M., Grothey, A., Shields, A.F., Seeber, A., Salem, M.E., Puccini, A., Tokunaga, R., Naseem, M., Arai, H., Wang, J., Berger, M.D., Zhang, W., Philip, P.A., Marshall, J.L., Korn, W.M., Lenz, H.J.

“…Although rare, the incidence of BM is increasing due to the improvement in metastatic CRC treatment and longer survival. Genomic analyses of small series…”
Get full text

1957P - Comparative molecular analyses between microsatellite stable BRAFV600E mutant colorectal cancers and BRAFV600E mutant melanomas by Salem, M.E., Xiu, J., Puccini, A., Grothey, A., Goldberg, R.M., Hwang, J.J., Gatalica, Z., Feldman, R., Saul, M., Korn, W.M., Hall, M.J., El-Deiry, W., Shields, A.F., Marshall, J.L., Lenz, H.J., VanderWalde, A.M.

“…Several studies in BRAFV600E colorectal cancers (CRC) have failed to replicate the efficacy of BRAF inhibitors in treatment of BRAFV600E melanomas (Mel),…”
Get full text

WRN mutated colorectal cancer (CRC) is characterized by a distinct molecular and immunological profile by Seeber, A., Puccini, A., Xiu, J., Baca, Y., Spizzo, G., Zimmer, K., Lenz, H.J., Battaglin, F., Goldberg, R.M., Grothey, A., Shields, A.F., Salem, M.E., Marshall, J.L., Korn, W.M., Wolf, D., Kocher, F.

Get full text

Comparative molecular analyses between microsatellite stable BRAFV600E mutant colorectal cancers and BRAFV600E mutant melanomas by Salem, M.E., Xiu, J., Puccini, A., Grothey, A., Goldberg, R.M., Hwang, J.J., Gatalica, Z., Feldman, R., Saul, M., Korn, W.M., Hall, M.J., El-Deiry, W., Shields, A.F., Marshall, J.L., Lenz, H.J., VanderWalde, A.M.

Get full text

Comprehensive molecular characterization of brain metastases (BM) from colorectal cancer (CRC) by Battaglin, F., Xiu, J., Baca, Y., Goldberg, R.M., Grothey, A., Shields, A.F., Seeber, A., Salem, M.E., Puccini, A., Tokunaga, R., Naseem, M., Arai, H., Wang, J., Berger, M.D., Zhang, W., Philip, P.A., Marshall, J.L., Korn, W.M., Lenz, H.J.

Get full text

645P - WRN mutated colorectal cancer (CRC) is characterized by a distinct molecular and immunological profile by Seeber, A., Puccini, A., Xiu, J., Baca, Y., Spizzo, G., Zimmer, K., Lenz, H.J., Battaglin, F., Goldberg, R.M., Grothey, A., Shields, A.F., Salem, M.E., Marshall, J.L., Korn, W.M., Wolf, D., Kocher, F.

“…Werner syndrome gene (WRN) encodes a DNA helicase with an exonuclease activity that contributes to DNA repair. In cancer, WRN mutations lead to genomic…”
Get full text

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers by El-Rayes, B.F., Zalupski, M., Bekai-Saab, T., Heilbrun, L.K., Hammad, N., Patel, B., Urba, S., Shields, A.F., Vaishampayan, U., Dawson, S., Almhanna, K., Smith, D., Philip, P.A.

“…Background: Bevacizumab has demonstrated antitumor activity in multiple diseases. This phase II study was undertaken to determine the effects of adding…”
Get full text